Abstract
Graves' disease is the most common etiology of thyrotoxicosis. 131I therapy is widely used to treat Graves' disease but may fail or course hypothyroidism. Thus, the study of prognostic factors of Graves' disease is of great clinical value. Research suggests that several factors, including the patient' s age, gender, course, serological indices, 131I therapy dose, thyroid volume and weight, effective half-life of 131I, technetium-99m pertechnetate thyroid uptake rate, radioactive iodine uptake rate, and thyroidal 131I turnover rate, may have important impacts on the results of 131I therapy; indeed, some of them remain controversial. The aim of this paper is to summarize the prognostic factors of 131I treatment to help clinicians decide on the best treatment route. Key words: Graves disease; Iodine radioisotopes; Brachytherapy; Prognosis
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
